Navigation Links
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Date:5/30/2009

se technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS), to effectively target and inhibit production of specific proteins in tumor cells. OncoGenex and Isis partnered in the successful discovery of OGX-011, OGX-427 and OGX-225 and with respect to OGX-011, in its initial development. In 2008, OncoGenex and Isis amended their OGX-011 agreement to provide OncoGenex with sole rights to OGX-011 and sole responsibility for development and related costs and partnering decisions, subject to financial obligations to Isis. OncoGenex is also solely responsible for development and related costs and partnering decisions regarding OGX-427 and OGX-225. Key intellectual property related to OGX-011, OGX-427 and OGX-225 were discovered by the University of British Columbia and the Vancouver Prostate Centre, and were exclusively licensed to OncoGenex.

More information about OncoGenex is available at www.oncogenex.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements concerning the potential survival benefit of OGX-011, anticipated clinical development activities, timing of these activities, the ability of future trials to demonstrate clinical benefit and the potential for regulatory approvals. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements.

The potential risks and uncertainties associated with forward-looking statements include, among
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
6. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
8. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
9. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
10. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
11. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... SAN DIEGO and BETHESDA, ... announced today that they are joining together with ... (NIH) to help scientists develop more reliable tools ... on a faster timeline. Organovo is collaborating with ... and the National Eye Institute (NEI) to develop ...
(Date:1/14/2014)... Jan. 14, 2014  RXi Pharmaceuticals Corporation ... discovering, developing and commercializing innovative therapies addressing ... today announced that it received the Notice ... and Trademark Office on its unique self-delivering ... fibrosis. The patent covers the use of ...
(Date:1/14/2014)... and Cardiff, UK (PRWEB) January 13, 2014 ... development leader with more than 20 years in the ... optics and photonics . Hainsey will serve as the ... to have Dr. Hainsey join SPIE as our Technology ... staff,” said Dr. Andrew Brown, SPIE Senior Director for ...
(Date:1/14/2014)... 2014 Independent publisher Bitingduck Press, with ... Canada, has big ideas for 2014 in production and ... are to produce high-quality, low-cost, DRM-free ebooks and to ... , The first major development will be bookstore ... called WebBytez . WebBytez is a patent-pending way ...
Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... becoming increasingly flatter - some have even become almost as ... dimensions, much to the delight of home cinema fans. Cellphones ... All of these developments owe their thanks to miniature light-emitting ... multitude of devices. However, LED technology does have a ...
... 16 Accuray Incorporated (Nasdaq: ARAY ), a global leader in ... at the Wells Fargo Securities Healthcare Conference in Boston on ... PT . , , , ... the presentation will be available online from the investor relations page of the ...
... Trans World Alloys (TWA), one of the country,s premier titanium sheet ... joined the company, as its new Chief Operating Officer. ACCORDING TO SANDY SHADROW, ... the metal business in a variety of areas." , ... Ed has attended the University of Baltimore , the ...
Cached Biology Technology:World of lights in the microcosmos 2Accuray Incorporated to Speak at Wells Fargo Securities Healthcare Conference 2Ed Brennan - New C.O.O. of Trans World Alloys 2
(Date:4/16/2014)... and soil processes are to blame for significant baseline ... a study published recently in the Journal of ... samples from all corners of Ohio showed that every ... of concern recommended by the U.S. Environmental Protection Agency. ... authors, who note that regulatory levels typically are set ...
(Date:4/16/2014)... Leo Heim and their colleagues at the University of ... of generating hydrogen using water and formaldehyde. The generation ... it comes to fuel cell technologies. The results of ... water and formaldehyde", have recently been published in the ... the new approach can be used to recycle industrial ...
(Date:4/15/2014)... Calif. UC Irvine neurobiologists have found that genetically ... into the brains of mice with the symptoms and ... in the journal Stem Cells Research and Therapy ... in two different mouse models. , Alzheimer,s disease, ... associated with accumulation of the protein amyloid-beta in the ...
Breaking Biology News(10 mins):Significant baseline levels of arsenic found in Ohio soils are due to natural processes 2Significant baseline levels of arsenic found in Ohio soils are due to natural processes 3Significant baseline levels of arsenic found in Ohio soils are due to natural processes 4UCI study finds modified stem cells offer potential pathway to treat Alzheimer's disease 2
... 2010) When researchers tested three different labeling agents ... effect the labeling agents had on stem cell phenotype, ... stem cell proliferation depending on the type of contrast ... and Spain tested USPIO (ultra small superparamagnetic iron oxide) ...
... voracious predatory crabs due to global warming could threaten ... published findings. "King crabs are ecologically important ... fisheries," said Dr Sven Thatje, an evolutionary ecologist at ... Science (SOES), which is based at the National Oceanography ...
... to spot prey, vision keeps many animals, including humans, alive. ... is it easier for us to spot movement of small ... things? The complexity of the neural network that supports vision ... and support from the National Science Foundation, Claire Wyart in ...
Cached Biology News:MRI contrast agents change stem cell proliferation 2King crab distributions limited by temperature in the Southern Ocean 2The zebrafish's neural circuit prevents it from biting off more than it can chew 2
PAb to Hu-IFN-Alpha/Beta R2 [(IFNAR2) CD118], Rabbit Serum, neutralizing Binds to but does not neutralize human interferon alpha/beta receptor...
IMAGEQUANT 100 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
Request Info...
RayBio Human Cytokine Antibody Array 1.1 (4 array membranes) with Accessory, detects 20 cytokines (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
Biology Products: